AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01953224 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Game-based intervention
Description: Investigators will provide participants with a smartphone and required accessories (gift card for downloading the game application and music, headphones, armband). The game, Zombies, Run! encourages walking/jogging by playing music interspersed with a continuous narrative. Periodic zombie chases encourage brief interval training. Participants will set goals to increase their activity and receive weekly brief counseling phone calls to provide feedback.
Study NCT01953224 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smartphone
Study NCT03789734 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BLS-M22
Description: BLS-M22 250mg/capsule
Study NCT01663324 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS intervention 2
Description: Repetitive transcranial magnetic stimulation (Magventure Mag Pro Option): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold).~Arms: multisite rTMS
Study NCT03789734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: BLS-M22 placebo 250mg/capsule
Study NCT00651859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.01% Ophthalmic Solution
Description: Bimatoprost 0.01% ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
Study NCT00651859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% Ophthalmic Solution
Description: Bimatoprost 0.03% ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
Study NCT00651859 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bimatoprost Vehicle Ophthalmic Solution
Description: Bimatoprost vehicle ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
Study NCT02966990 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hand Orthotic Devices
Description: Orthotic device made to provide the patient with better hand function
Study NCT04358380 — intervention group
Intervention type: OTHER
Intervention: Liver injury
Description: LFTs elevation or liver decompensation
Study NCT01533025 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anterior cruciate ligament reconstruction
Description: single bundle anterior cruciate ligament reconstruction with Achilles allograft
Study NCT02518750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given orally (PO).
Study NCT02518750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Given PO.
Study NCT02518750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal vincristine
Description: For intravenous (IV) use only.
Study NCT02518750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Given IV.
Study NCT02518750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peg-asparaginase
Description: Given IV or intramuscularly (IM).~In case of allergy or intolerance to Peg-asparaginase, Erwinia L-asparaginase (Erwinase®) will be used. Erwinia L-asparaginase is given by either IV or IM injection.
Study NCT02518750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given by IV push over 3 to 5 seconds. For IV use only.
Study NCT02142517 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Duct to mucosa PJ group
Description: Duct to mucosa PJ was performed by a two layer end to side PJ. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic duct diameter. The inner layer duct to mucosa was performed in eight to twelve stitches with 5/0 prolene. A pancreatic duct stent was inserted during anastomosis to allow easy and accurate suture placement, ensure adequate pancreatic duct exposure, and protect the opposite wall from being inadvertently held by needles then it was removed at the end of anastomosis.
Study NCT02142517 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Invagination PJ group
Description: Invagination PJ was performed as an end to side. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic stump diameter. The inner layer was performed with 5/0 prolene between pancreatic parenchyma and mucosa. The duct was taken posteriorly and anteriorly to jejunal mucosa. A pancreatic duct stent was inserted during anastomosis and removed at the end of taking the stitches. Reconstruction was completed by end to side hepaticojejunostomy (retrocolic) and gastrojejunostomy (GJ) (antecolic) end to side manually.
Study NCT00895752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole
Description: Six week open-label treatment with riluzole, maximum dose of 50 mg twice a day.
Study NCT00001721 — intervention group
Intervention type: DRUG
Intervention: Cholesterol Suspension
Study NCT01892787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: Participants receive Atimos for 1 to 2 weeks.Partcipants then enter a washout period and after the washout period receive the alternative treatment arm.
Study NCT01892787 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: Participants receive Serevent for 1 to 2 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
Study NCT02511483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol PO
Description: 20 mg PO BID Day of Surgery, 30 mg PO BID Day I and Day II post-op.
Study NCT02511483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IV-PCA morphine
Description: Morphine delivered via IV-PCA pump for 48 hours after surgery with standard program: bolus 1 mg, lock out 7 minutes, no background infusion.
Study NCT02511483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV-PCA morphine
Description: Morphine delivered via IV-PCA pump for 48 hours after surgery with standard program: bolus 1 mg, lock out 7 minutes, no background infusion.
Study NCT02511483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PO
Description: Placebo tablets administered with the same schedule of Propranolol tablets
Study NCT02511483 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Quantitative Sensory Testing (QST)
Description: Assessment of PPT (Pressure Pain Threshold) by pressure algometer and assessment of the post-op area of hyperalgesia by von Frey hair no. 16.
Study NCT02511483 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quantitative Sensory Testing (QST)
Description: Assessment of PPT (Pressure Pain Threshold) by pressure algometer and assessment of the post-op area of hyperalgesia by von Frey hair no. 16.
Study NCT02511483 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Psychometric assessment
Description: Questionnaires assessing for sleep quality (PSQI: Pittsburgh Sleep Quality Index), pain quality (sfMGPQ-Short Form-McGill Pain Questionnaire), somatization-depression-anxiety (SCL-90-R: Symptom Checklist 90 Revised), evolution of post-operative chronic pain (PQRS: Post-operative Quality of Recovery Scale)
Study NCT02518750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Triples
Description: Given IT as ITMHA.
Study NCT02518750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate
Description: Given intrathecally (IT) or IV.
Study NCT02518750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-Mercaptopurine
Description: Given PO at consistent time each day.
Study NCT02518750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose cytarabine
Description: Given IT or IV.
Study NCT02518750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelarabine
Description: Given IV
Study NCT02518750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV.
Study NCT02518750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV.~In case of etoposide reactions, IV etoposide phosphate (Etopophos®) will be used.
Study NCT02518750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Given IV.~Clofarabine will be given instead of nelarabine for patients with B-lymphoblastic leukemia and lymphoma in stratum II.
Study NCT00001721 — intervention group
Intervention type: DRUG
Intervention: CRH
Study NCT00001721 — intervention group
Intervention type: DRUG
Intervention: Cholesterol
Study NCT00001723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orlistat
Description: Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.
Study NCT00001723 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.
Study NCT03916276 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Therapy (CT)
Description: The cognitive-restructuring technique will be used to help participants recognize the relationships between thoughts, feelings, behaviors, and pain. This technique will help participants: (1) identify negative or unrealistic automatic thoughts; (2) evaluate automatic thoughts for accuracy, identify sources of distorted thoughts; recognize the connection between automatic thoughts and emotional/physical shifts; (3) challenge negative, distorted automatic thoughts via weighing the evidence; (4) develop new realistic alternative cognitive appraisals; and (5) practice applying new rational appraisals and beliefs.
Study NCT03916276 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness Meditation (MM)
Description: Participants will receive training in mindfulness meditation, specifically Vipassana, which is the form of meditation typically implemented in mindfulness research. With this technique, the emphasis is placed upon developing focused attention on an object of awareness, e.g., the breath. This focus is then expanded to include a more open, non-judgmental monitoring of any sensory, emotional, or cognitive events. A standard script will be implemented by the clinician, and participants will be seated in a comfortable yet alert position.
Study NCT03916276 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Activation Skills (AS)
Description: Participants will be educated about the role of inactivity and behavioral avoidance in chronic pain and functioning. They will learn how to be aware of the activities they avoid because of pain, and how to set effective goals so that, step by step, they can start being more active and resume some activities they enjoyed in the past but are currently avoiding. Explanation and practice of a set of specific skills - including appropriate pacing skills - to facilitate an increase in appropriate activity level will be provided.
Study NCT02788357 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: Subjects will receive a single daily oral dose of 40 mg of atomoxetine. We will administer 2 hours/daily of motor training sixty minutes after drug intake.
Study NCT02788357 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive a single daily oral dose of placebo. We will administer 2 hours/daily of motor training sixty minutes after drug intake.
Study NCT02511483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychometric assessment
Description: Questionnaires assessing for sleep quality (PSQI: Pittsburgh Sleep Quality Index), pain quality (sfMGPQ-Short Form-McGill Pain Questionnaire), somatization-depression-anxiety (SCL-90-R: Symptom Checklist 90 Revised), evolution of post-operative chronic pain (PQRS: Post-operative Quality of Recovery Scale)
Study NCT02511483 — intervention group
Intervention type: GENETIC
Group type: PLACEBO_COMPARATOR
Intervention: COMT-haplotypes
Description: Assessing of High Pain Sensitivity (HPS), Average Pain Sensitivity (APS) and Low Pain Sensitivity (LPS) haplotypes for COMT by genotyping peripheral blood samples.
Study NCT02511483 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: COMT-haplotypes
Description: Assessing of High Pain Sensitivity (HPS), Average Pain Sensitivity (APS) and Low Pain Sensitivity (LPS) haplotypes for COMT by genotyping peripheral blood samples.
Study NCT03354546 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Frailty index
Description: A frailty index composed of variables from health administrative data that cover multi-system health issues. Deficits will be coded as present or absent, and the number of deficits present will be divided by the total number of deficits present to provide an overall score between 0-1.
Study NCT03014310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS03
Description: AS03 oil-in-water emulsion adjuvant.
Study NCT03014310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MF59
Description: Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
Study NCT03014310 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monovalent Influenza A/H5N8 vaccine
Description: Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).
Study NCT03014310 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Monovalent Influenza A/H5N8 vaccine
Description: Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).
Study NCT03647410 — intervention group
Intervention type: DEVICE
Intervention: lumbopelvic fixation
Description: Sacral fractures fixed with lumbopelvic fixation or novel adjustable plate were divided into two groups. Surgical time, intraoperative blood loss, frequency of intraoperative fluoroscopy, reduction quality, related complications, and functional outcome were reviewed.
Study NCT04570605 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: parasacral transcutaneous electrical nerve stimulation (PTENS)
Description: electrode patches placed on skin of lower back just above each side of the gluteal cleft (parasacral) and attached to TENS unit at specific settings three times a week for 30 minutes for 12 weeks.
Study NCT04570605 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Urotherapy
Description: standard behavioral therapy recommendations including timed voiding, fluid intake recommendations and bowel management recommendations including videos instructing patients and parents on these issues. This is current standard of care.
Study NCT04570605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Urotherapy
Description: standard behavioral therapy recommendations including timed voiding, fluid intake recommendations and bowel management recommendations including videos instructing patients and parents on these issues. This is current standard of care.
Study NCT00926419 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella Vaccine
Description: Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain)
Study NCT00926419 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varicella Vaccine
Description: Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain)
Study NCT00926419 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis A Vaccine
Description: Hepatitis A virus vaccine, inactivated, Single dose
Study NCT00926419 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hepatitis A Vaccine
Description: Hepatitis A virus vaccine, inactivated, Single dose
Study NCT02853812 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Functional brain MRI
Description: Sound evoked functional MRI assessment on patients with single sided tinnitus
Study NCT02370485 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2801653
Description: Administered orally
Study NCT04466098 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells
Description: Thawed product containing MSC(300x10\^6) in DMSO resuspended 1:1 with Dextran 40 + 5% human serum albumin \[total volume 60 mL\]
Study NCT04466098 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dextran 40 + 5% human serum albumin \[total volume 60 mL\]
Study NCT00709527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avacincaptad Pegol
Description: intravitreal injection
Study NCT04288128 — intervention group
Intervention type: PROCEDURE
Intervention: Lumbar puncture
Description: Each participant will undergo lumbar puncture at first visit (M0) and last visit (M12)
Study NCT04288128 — intervention group
Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: Each participant will undergo scanning at 3 visits (M0, M6 and M12)
Study NCT04209543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estetrol
Description: Estetrol oral tablet: administered orally once daily
Study NCT04209543 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral tablet: administered orally once daily
Study NCT04209543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Progesterone oral tablet: administered orally once daily
Study NCT03952559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study NCT03952559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT03952559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical corticosteroid
Description: Administered as standard-of-care
Study NCT03952559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical corticosteroid
Description: Administered as standard-of-care
Study NCT01730664 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ertapenem
Description: single dose of 2000mg ertapenem IV
Study NCT01465217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: text message medication reminders
Description: daily medication reminders for one month
Study NCT03944772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Osimertinib given orally at 80 mg once daily
Study NCT03944772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: Savolitinib will be given orally at 300 mg or 600mg once daily
Study NCT03944772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Gefitinib given orally at 250 mg once daily
Study NCT03944772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Necitumumab
Description: Necitumumab given IV at 800 mg on Day 1 and Day 8 of every 3-week cycle
Study NCT03944772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab given IV at 1500 mg on Day 1 of every cycle
Study NCT03944772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin given IV on Day 1 of every 21-day cycle for up to 6 cycles
Study NCT03944772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed given IV at 500 mg/m2 body BSA on Day 1 of every cycle
Study NCT03944772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alectinib
Description: Alectinib given orally at 600mg twice daily and for Japanese patients at 300mg twice daily.
Study NCT03944772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selpercatinib
Description: Selpercatinib given orally at 160mg twice daily
Study NCT03944772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Selumetinib given orally at 75 mg twice daily for 4 days, followed by 3 days off treatment
Study NCT03944772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 80-100 mg/m2 given IV on day 1, 2 and 3 of every 21-day cycle for up to 4 cycles.
Study NCT03944772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75-80 mg/m2 given IV on days 1 of each cycle
Study NCT03944772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan
Description: Datopotamab deruxtecan given IV at 4 or 6 mg/kg on Day 1 of every 3-week cycle.
Study NCT04000971 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Stroke Practice Unit
Description: Care teams will follow patients in their home or rehabilitation/skilled nursing facility monthly for 12 visits to assess recovery, manage risk factors, and increase understanding and build positive behavior change for patients and caregivers. Primary and secondary outcomes will be assessed at 3, 6, and 12 months.